Literature DB >> 16981691

Mechanistic study of HCV polymerase inhibitors at individual steps of the polymerization reaction.

Yaya Liu1, Wen W Jiang, John Pratt, Todd Rockway, Kevin Harris, Sudthida Vasavanonda, Rakesh Tripathi, Ron Pithawalla, Warren M Kati.   

Abstract

Little is known about the mechanism of HCV polymerase-catalyzed nucleotide incorporation and the individual steps employed by this enzyme during a catalytic cycle. In this paper, we applied various biochemical tools and examined the mechanism of polymerase catalysis. We found that formation of a productive RNA-enzyme complex is the slowest step followed by RNA dissociation and initiation of primer strand synthesis. Various groups have reported several classes of small molecule inhibitors of hepatitis C virus NS5B polymerase; however, the mechanism of inhibition for many of these inhibitors is not clear. We undertook a series of detailed mechanistic studies to characterize the mechanisms of inhibition for these HCV polymerase inhibitors. We found that the diketoacid derivatives competitively bind to the elongation NTP pocket in the active site and inhibit both the initiation and elongation steps of polymerization. While both benzimidazoles and benzothiadiazines are noncompetitive with respect to the active site elongation NTP pocket, benzothiadiazine compounds competitively bind to the initiation pocket in the active site and inhibit only the initiation step of de novo RNA polymerization. The benzimidazoles bind to the thumb allosteric pocket and inhibit the conformational changes during RNA synthesis. We also observed a cross interaction between the thumb allosteric pocket and the initiation pocket using inhibitor-inhibitor cross competition studies. This information will be very important in designing combination therapies using two small molecule drugs to treat hepatitis C virus.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16981691     DOI: 10.1021/bi060511j

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  22 in total

1.  Helicase inhibitors as specifically targeted antiviral therapy for hepatitis C.

Authors:  Craig A Belon; David N Frick
Journal:  Future Virol       Date:  2009-05-01       Impact factor: 1.831

2.  miR-122 does not modulate the elongation phase of hepatitis C virus RNA synthesis in isolated replicase complexes.

Authors:  Rodrigo A Villanueva; Rohit K Jangra; Minkyung Yi; Rick Pyles; Nigel Bourne; Stanley M Lemon
Journal:  Antiviral Res       Date:  2010-07-14       Impact factor: 5.970

3.  Activity of a potent hepatitis C virus polymerase inhibitor in the chimpanzee model.

Authors:  Chih-Ming Chen; Yupeng He; Liangjun Lu; Hock Ben Lim; Rakesh L Tripathi; Tim Middleton; Lisa E Hernandez; David W A Beno; Michelle A Long; Warren M Kati; Todd D Bosse; Daniel P Larson; Rolf Wagner; Robert E Lanford; William E Kohlbrenner; Dale J Kempf; Tami J Pilot-Matias; Akhteruzzaman Molla
Journal:  Antimicrob Agents Chemother       Date:  2007-10-01       Impact factor: 5.191

4.  Structural and functional analysis of hepatitis C virus strain JFH1 polymerase.

Authors:  Philip Simister; Melanie Schmitt; Matthis Geitmann; Oliver Wicht; U Helena Danielson; Rahel Klein; Stéphane Bressanelli; Volker Lohmann
Journal:  J Virol       Date:  2009-09-09       Impact factor: 5.103

5.  Synthesis and SAR optimization of diketo acid pharmacophore for HCV NS5B polymerase inhibition.

Authors:  Aaditya Bhatt; K R Gurukumar; Amartya Basu; Maulik R Patel; Neerja Kaushik-Basu; Tanaji T Talele
Journal:  Eur J Med Chem       Date:  2011-08-26       Impact factor: 6.514

6.  Mechanism of hepatitis C virus RNA polymerase inhibition with dihydroxypyrimidines.

Authors:  Megan H Powdrill; Jerome Deval; Frank Narjes; Raffaele De Francesco; Matthias Götte
Journal:  Antimicrob Agents Chemother       Date:  2009-12-22       Impact factor: 5.191

7.  Slow binding inhibition and mechanism of resistance of non-nucleoside polymerase inhibitors of hepatitis C virus.

Authors:  Julie Qi Hang; Yanli Yang; Seth F Harris; Vincent Leveque; Hannah J Whittington; Sonal Rajyaguru; Gloria Ao-Ieong; Matthew F McCown; April Wong; Anthony M Giannetti; Sophie Le Pogam; Francisco Talamás; Nick Cammack; Isabel Nájera; Klaus Klumpp
Journal:  J Biol Chem       Date:  2009-02-26       Impact factor: 5.157

8.  Thumb inhibitor binding eliminates functionally important dynamics in the hepatitis C virus RNA polymerase.

Authors:  Brittny C Davis; Ian F Thorpe
Journal:  Proteins       Date:  2012-09-15

9.  Inhibition of hepatitis C virus (HCV) RNA polymerase by DNA aptamers: mechanism of inhibition of in vitro RNA synthesis and effect on HCV-infected cells.

Authors:  Pantxika Bellecave; Christian Cazenave; Julie Rumi; Cathy Staedel; Ophélie Cosnefroy; Marie-Line Andreola; Michel Ventura; Laura Tarrago-Litvak; Thérèse Astier-Gin
Journal:  Antimicrob Agents Chemother       Date:  2008-03-17       Impact factor: 5.191

10.  Hepatitis C virus NS5B polymerase exhibits distinct nucleotide requirements for initiation and elongation.

Authors:  Eric Ferrari; Zhiqing He; Robert E Palermo; H-C Huang
Journal:  J Biol Chem       Date:  2008-10-06       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.